Brief: OSE Immunotherapeutics Partners With GenDx To Develop Companion Diagnostic For Cancer Vaccine

Ose Immunotherapeutics SA

21/11/2023 17:06

Nov 21 (Reuters) - OSE Immunotherapeutics SA  OSE.PA :
    * ANNOUNCES A COLLABORATION AGREEMENT WITH GENDX FOR THE
DEVELOPMENT OF A COMPANION DIAGNOSTIC FOR EPITOPE-BASED CANCER
VACCINE CANDIDATE TEDOPI®
    * DEVELOPMENT PROGRAM TO SUPPORT IN PARALLEL NEXT
CONFIRMATORY
PIVOTAL PHASE 3 CLINICAL TRIAL UNDER PREPARATION
    * A COMPANION DIAGNOSTIC TEST TO IDENTIFY HLA-A*02 POSITIVE
CANCER
PATIENTS ELIGIBLE FOR TREATMENT WITH TEDOPI®
    * OBJECTIVE OF STUDY: TO CONFIRM EFFICACY, SAFETY OF TEDOPI®
IN
SECOND LINE TREATMENT POST-IMMUNE CHECKPOINT INHIBITOR (ICI)
FAILURE IN HLA-A*02 POSITIVE NSCLC PATIENTS TO SUPPORT TEDOPI®'S
REGISTRATION IN US, EUROPE

Source text for Eikon:  ID:nBw5xkcPna 
Further company coverage:  OSE.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))